Summary
High-dose chemotherapy and autologous bone marrow transplantation (ABMT) are commonly used to treat selected patients with high-risk breast cancer. A limitation of ABMT is that clonogenic cancer cells could be collected with the bone marrow and produce a relapse of disease when reinfused into patients. Purging the marrowex vivo may eliminate the tumor cells, but it can also delay engraftment. We employed two different purging methods whereby breast cancer cells were depleted without delaying engraftment. The addition of WR-2721 (amifostine) to 4-hydroperoxycyclophosphamide (4-HC) reduced the time to engraftment by 10 days compared with marrow purged with 4-HC alone (26 versus 37 days, respectively). The positive selection of CD34+ hematopoietic progenitors produced engraftment within 21 days. The use of granulocyte colony-stimulating factor (G-CSF) accelerated the engraftment time of CD34+ hematopoietic progenitors to 11 days.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yeager A, Kaizer H, Santos G, Saral R, Colvin M, Stuart R, Braine H, Burke P, Aambinder R, Burns W, Fuller D, Davis J, Karp J: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315: 144–147, 1986
Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone A, Gorin N, Flesh M, Laporte JP, Maranillas F, Dicke K: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493–1498, 1987
Peters WP, Davis R, Shpall EJ, Jones RB, Ross M, Marks L, Norton L, Hurd D: Adjuvant chemotherapy involving high-dose combination cyclophosphamide, BCNU, and cisplatin with bone marrow support for stage II/III breast cancer involving ten or more lymph nodes(CALGB 8782): a preliminary report (Abstract). Proc Am Soc Clin Oncol 31:22, 1990
Dicke K, Vellekoop L, Zander A, Jagannath S, Poytiron C, Lichtiger B, Verma D, Spitzer G: Autologous transplantation in acute leukemia. Surv Synth Pathol Res 4:84–96, 1985
Shpall EJ, Jones RB, Bast RC, Rosner G, Vandermark M, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperberg M, Coniglio D, Peters WP: 4-hydroperoxycyclophosphamide (4-HC) purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9:85–93, 1990
Wasserman TH, Phillips TL, Ross G, Kane L: Differential protection against chemotherapeutic effects on bone marrow CFUs by WR2721. Cancer Clin Trials 4: 3–6, 1981
Shpall EJ, Jones RB, Johnston C, Schein P, Peters WP, Seigler H: Purging of breast cancer cells from bone marrow using WR-2721 and 4-hydroperoxycyclophosphamide (Abstract). Proc Am Assoc Cancer Res 31: 1992, 1990
Andrews RG, Singer JW, Bernstein ID: Monoclonal antibody 12-8 recognized a 115-kDa molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 67: 842–845, 1986
Berenson RJ, Bensinger WI, Kalamasz D, et al: Avidin-biotin immunoadsorption: a technique to purify cells and its potential applications.In: Gale RP, Champlin R (eds) Progress in Bone Marrow Transplantation. Alan R. Liss, New York, 1987, pp 423–428
Shpall EJ, Jones RB, Johnston C, Hami L, Stemmer S, Affronti ML, Curiel T, Berenson R: Purified CD34-positive marrow progenitors provide effective reconstitution for breast cancer patients receiving high-dose chemotherapy and ABMT: recombinant GCSF accelerates hematopoietic recovery (Abstract). Proc Am Soc Clin Oncol 11:59, 1992
Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hent L, Halpern T, Iglehart D, Moore J, Gockerman J, Bast RC Sr, Peters WP: The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer. Cancer 66:431–436, 1990
Peters WP, Shpall EJ, Jones RB, Olsen G, Bast RC, Gockerman J, Moore J: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368–1375, 1988
Gorin NC, Aegerter B, Auvert G, Meloni AH, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Lowenberg R, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM: Autologous bone marrow transplantation for acute myelogenous leukemia in first remission: a European survey of the role of marrow purging. Blood 75:1606–1614, 1990
Gribben JC, Goldstone AH, Linch DC, Taghipour G, McMillan AK, Souhami RL, Earl H, Richards JDM: Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still responsive to conventional-dose therapy. J Clin Oncol 7:1621–1629, 1989
Cote RJ, Rosen PR, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult metastases. J Clin Oncol 9:1749–1756, 1991
Vaughn WP, Mann SL, Garvey J, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD: Breast cancer detected in cell culture of histologically negative bone marrow predicts systemic relapse in patients with stage I, II, III, and locally recurrent disease (Abstract). Proc Am Soc Clin Oncol 9:9, 1990
Author information
Authors and Affiliations
Additional information
Held in conjunction with the 15th Annual San Antonio Breast Cancer Symposium, December 1992, and supported by an educational grant from Lederle Oncology; editing by The Medicine Group USA, Inc.
Rights and permissions
About this article
Cite this article
Shpall, E.J., Stemmer, S.M., Bearman, S.I. et al. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. Breast Cancer Res Tr 26, S19–S23 (1993). https://doi.org/10.1007/BF00668356
Issue Date:
DOI: https://doi.org/10.1007/BF00668356